Envelope glycoprotein GP350

Details

Name
Envelope glycoprotein GP350
Synonyms
  • MA
  • Membrane antigen
Gene Name
Not Available
Organism
HHV-4
Amino acid sequence
>lcl|BSEQ0001185|Envelope glycoprotein GP350
MEAALLVCQYTIQSLIHLTGEDPGFFNVEIPEFPFYPTCNVCTADVNVTINFDVGGKKHQ
LDLDFGQLTPHTKAVYQPRGAFGGSENATNLFLLELLGAGELALTMRSKKLPINVTTGEE
QQVSLESVDVYFQDVFGTMWCHHAEMQNPVYLIPETVPYIKWDNCNSTNITAVVRAQGLD
VTLPLSLPTSAQDSNFSVKTEMLGNEIDIECIMEDGEISQVLPGDNKFNITCSGYESHVP
SGGILTSTSPVATPIPGTGYAYSLRLTPRPVSRFLGNNSILYVFYSGNGPKASGGDYCIQ
SNIVFSDEIPASQDMPTNTTDITYVGDNATYSVPMVTSEDANSPNVTVTAFWAWPNNTET
DFKCKWTLTSGTPSGCENISGAFASNRTFDITVSGLGTAPKTLIITRTATNATTTTHKVI
FSKAPESTTTSPTLNTTGFADPNTTTGLPSSTHVPTNLTAPASTGPTVSTADVTSPTPAG
TTSGASPVTPSPSPWDNGTESKAPDMTSSTSPVTTPTPNATSPTPAVTTPTPNATSPTPA
VTTPTPNATSPTLGKTSPTSAVTTPTPNATSPTLGKTSPTSAVTTPTPNATSPTLGKTSP
TSAVTTPTPNATGPTVGETSPQANATNHTLGGTSPTPVVTSQPKNATSAVTTGQHNITSS
STSSMSLRPSSNPETLSPSTSDNSTSHMPLLTSAHPTGGENITQVTPASISTHHVSTSSP
APRPGTTSQASGPGNSSTSTKPGEVNVTKGTPPQNATSPQAPSGQKTAVPTVTSTGGKAN
STTGGKHTTGHGARTSTEPTTDYGGDSTTPRPRYNATTYLPPSTSSKLRPRWTFTSPPVT
TAQATVPVPPTSQPRFSNLSMLVLQWASLAVLTLLLLLVMADCAFRRNLSTSHTYTTPPY
DDAETYV
Number of residues
907
Molecular Weight
94430.75
Theoretical pI
5.42
GO Classification
Processes
viral life cycle
Components
host cell membrane / integral component of membrane / viral envelope / virion membrane
General Function
Not Available
Specific Function
Initiates virion attachment to host B-lymphocyte cell, leading to virus entry. Acts by binding to host CR2 at the surface of B-lymphocytes, facilitating the binding of viral glycoprotein gp42 to HLA class II molecules. Attachment triggers virion-host membrane fusion and invasion of the host cell.
Pfam Domain Function
Transmembrane Regions
861-881
Cellular Location
Virion membrane
Gene sequence
>lcl|BSEQ0010412|Envelope glycoprotein GP350
ATGGAGGCAGCCTTGCTTGTGTGTCAGTACACCATCCAGAGCCTGATCCATCTCACGGGT
GAAGATCCTGGTTTTTTCAATGTTGAGATTCCGGAATTCCCATTTTACCCCACATGCAAT
GTTTGCACGGCAGATGTCAATGTAACTATCAATTTCGATGTCGGGGGCAAAAAGCATCAA
CTTGATCTTGACTTTGGCCAGCTGACACCCCATACGAAGGCTGTCTACCAACCTCGAGGT
GCATTTGGTGGCTCAGAAAATGCCACCAATCTCTTTCTACTGGAGCTCCTTGGTGCAGGA
GAATTGGCTCTAACTATGCGGTCTAAGAAGCTTCCAATTAACGTCACCACCGGAGAGGAG
CAACAAGTAAGCCTGGAATCTGTAGATGTCTACTTTCAAGATGTGTTTGGAACCATGTGG
TGCCACCATGCAGAAATGCAAAACCCCGTGTACCTGATACCAGAAACAGTGCCATACATA
AAGTGGGATAACTGTAATTCTACCAATATAACGGCAGTAGTGAGGGCACAGGGGCTGGAT
GTCACGCTACCCTTAAGTTTGCCAACGTCAGCTCAAGACTCGAATTTCAGCGTAAAAACA
GAAATGCTCGGTAATGAGATAGATATTGAGTGTATTATGGAGGATGGCGAAATTTCACAA
GTTCTGCCCGGAGACAACAAATTTAACATCACCTGCAGTGGATACGAGAGCCATGTTCCC
AGCGGCGGAATTCTCACATCAACGAGTCCCGTGGCCACCCCAATACCTGGTACAGGGTAT
GCATACAGCCTGCGTCTGACACCACGTCCAGTGTCACGATTTCTTGGCAATAACAGTATC
CTGTACGTGTTTTACTCTGGGAATGGACCGAAGGCGAGCGGGGGAGATTACTGCATTCAG
TCCAACATTGTGTTCTCTGATGAGATTCCAGCTTCACAGGACATGCCGACAAACACCACA
GACATCACATATGTGGGTGACAATGCTACCTATTCAGTGCCAATGGTCACTTCTGAGGAC
GCAAACTCGCCAAATGTTACAGTGACTGCCTTTTGGGCCTGGCCAAACAACACTGAAACT
GACTTTAAGTGCAAATGGACTCTCACCTCGGGGACACCTTCGGGTTGTGAAAATATTTCT
GGTGCATTTGCGAGCAATCGGACATTTGACATTACTGTCTCGGGTCTTGGCACGGCCCCC
AAGACACTCATTATCACACGAACGGCTACCAATGCCACCACAACAACCCACAAGGTTATA
TTCTCCAAGGCACCCGAGAGCACCACCACCTCCCCTACCTTGAATACAACTGGATTTGCT
GATCCCAATACAACGACAGGTCTACCCAGCTCTACTCACGTGCCTACCAACCTCACCGCA
CCTGCAAGCACAGGCCCCACTGTATCCACCGCGGATGTCACCAGCCCAACACCAGCCGGC
ACAACGTCAGGCGCATCACCGGTGACACCAAGTCCATCTCCATGGGACAACGGCACAGAA
AGTAAGGCCCCCGACATGACCAGCTCCACCTCACCAGTGACTACCCCAACCCCAAATGCC
ACCAGCCCCACCCCAGCAGTGACTACCCCAACCCCAAATGCCACCAGCCCCACCCCAGCA
GTGACTACCCCAACCCCAAATGCCACCAGCCCCACCTTGGGAAAAACAAGTCCTACCTCA
GCAGTGACTACCCCAACCCCAAATGCCACCAGCCCCACCTTGGGAAAAACAAGCCCCACC
TCAGCAGTGACTACCCCAACCCCAAATGCCACCAGCCCCACCTTGGGAAAAACAAGCCCC
ACCTCAGCAGTGACTACCCCAACCCCAAATGCCACCGGCCCTACTGTGGGAGAAACAAGT
CCACAGGCAAATGCCACCAACCACACCTTAGGAGGAACAAGTCCCACCCCAGTAGTTACC
AGCCAACCAAAAAATGCAACCAGTGCTGTTACCACAGGCCAACATAACATAACTTCAAGT
TCAACCTCTTCCATGTCACTGAGACCCAGTTCAAACCCAGAGACACTCAGCCCCTCCACC
AGTGACAATTCAACGTCACATATGCCTTTACTAACCTCCGCTCACCCAACAGGTGGTGAA
AATATAACACAGGTGACACCAGCCTCTATCAGCACACATCATGTGTCCACCAGTTCGCCA
GCACCCCGCCCAGGCACCACCAGCCAAGCGTCAGGCCCTGGAAACAGTTCCACATCCACA
AAACCGGGGGAGGTTAATGTCACCAAAGGCACGCCCCCCCAAAATGCAACGTCGCCCCAG
GCCCCCAGTGGCCAAAAGACGGCGGTTCCCACGGTCACCTCAACAGGTGGAAAGGCCAAT
TCTACCACCGGTGGAAAGCACACCACAGGACATGGAGCCCGGACAAGTACAGAGCCCACC
ACAGATTACGGCGGTGATTCAACTACGCCAAGACCGAGATACAATGCGACCACCTATCTA
CCTCCCAGCACTTCTAGCAAACTGCGGCCCCGCTGGACTTTTACGAGCCCACCGGTTACC
ACAGCCCAAGCCACCGTGCCAGTCCCGCCAACGTCCCAGCCCAGATTCTCAAACCTCTCC
ATGCTAGTACTGCAGTGGGCCTCTCTGGCTGTGCTGACCCTTCTGCTGCTGCTGGTCATG
GCGGACTGCGCCTTTAGGCGTAACTTGTCTACATCCCATACCTACACCACCCCACCATAT
GATGACGCCGAGACCTATGTATAA
Chromosome Location
Not Available
Locus
Not Available
External Identifiers
ResourceLink
UniProtKB IDP03200
UniProtKB Entry NameGP350_EBVB9
GenBank Protein ID1334868
GenBank Gene IDV01555
General References
  1. Baer R, Bankier AT, Biggin MD, Deininger PL, Farrell PJ, Gibson TJ, Hatfull G, Hudson GS, Satchwell SC, Seguin C, et al.: DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature. 1984 Jul 19-25;310(5974):207-11. [Article]
  2. Beisel C, Tanner J, Matsuo T, Thorley-Lawson D, Kezdy F, Kieff E: Two major outer envelope glycoproteins of Epstein-Barr virus are encoded by the same gene. J Virol. 1985 Jun;54(3):665-74. [Article]
  3. Morgan AJ, Smith AR, Barker RN, Epstein MA: A structural investigation of the Epstein-Barr (EB) virus membrane antigen glycoprotein, gp340. J Gen Virol. 1984 Feb;65 ( Pt 2):397-404. [Article]
  4. Morgan AJ: Epstein-Barr virus vaccines. Vaccine. 1992;10(9):563-71. [Article]
  5. Johannsen E, Luftig M, Chase MR, Weicksel S, Cahir-McFarland E, Illanes D, Sarracino D, Kieff E: Proteins of purified Epstein-Barr virus. Proc Natl Acad Sci U S A. 2004 Nov 16;101(46):16286-91. Epub 2004 Nov 8. [Article]
  6. Young KA, Herbert AP, Barlow PN, Holers VM, Hannan JP: Molecular basis of the interaction between complement receptor type 2 (CR2/CD21) and Epstein-Barr virus glycoprotein gp350. J Virol. 2008 Nov;82(22):11217-27. doi: 10.1128/JVI.01673-08. Epub 2008 Sep 10. [Article]

Drug Relations

Drug Relations
DrugBank IDNameDrug groupPharmacological action?ActionsDetails
DB00632Docosanolapproved, investigationalyesintercalationDetails